Changchun University of Chinese Medicine Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Changchun China (1958)

Organization Overview

First Clinical Trial
2012
NCT01274936
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Affiliated Hospital of Changchun University of Chinese Medicine | Changchun Traditional Medicine University Affiliated Hospital | Changchun University of Chinese Medicine | Children's Hospital of Changchun | Jilin Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Changchun University of Traditional Chinese Medicine | The Affiliated Hospital of Changchun University of Chinese Medicine

Active Ingredients

Drugs in Phase 4 Trials (2)

fufangshuanghua (1 trial)

jinyebaidu (1 trial)

Drugs in Phase 2 Trials (3)

buqitongluo (1 trial)

qishen (1 trial)

yangxinshi (1 trial)

Drugs in Phase 1 Trials (1)

mudan (1 trial)

Drugs in Other Trials (2)

jian pi yi shen hua tan (1 trial)

methylprednisolone (medrol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angina Pectoris (Phase 2)

Angina, Stable (Phase 2)

Blind Loop Syndrome (Phase 2)

Communicable Diseases (Phase 4)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Heart Diseases (Phase 2)

Infections (Phase 4)

Myocardial Ischemia (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Radiculopathy (Phase 2)

Respiratory Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 8